Lumida
/RGNX
⌘K
Regenxbio Inc

Regenxbio Inc

RGNX
$9.66USD+3.09%+0.29 today

MARKET CAP

637.7M

P/E (TTM)

FWD P/E

DAY RANGE

$9 – $10

52W RANGE

$5
$16

AI Summary

Stalk
StalkMedium

RGNX remains in a Stage 2 advance with clear higher highs and higher lows supported by rising short-term EMAs and expanding volume. The active Momentum Breakout signals new demand overwhelming prior supply at resistance. Price is extended above EMAs and in overbought territory, so short-term timing is unclear—execution should be deferred to pullbacks into rising EMA support or the breakout zone. Medium-term bias stays bullish while the long-term trend remains bearish.

  • RGX202 achieved its primary endpoint with high significance; FDA approval expected 2026.
  • $364M cash runway funds operations into early 2027, plus $100M in milestone potential.
  • Weak profitability and negative earnings yield raise viability concerns.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$470.3M$112.7M$90.2M$83.3M$170.4M
YoY %+204.3%-76.0%-19.9%-7.7%+104.5%
P / Sales3.1x8.5x8.9x4.6x4.4x
EV / Sales3.1x10.5x11.4x6.4x6.2x
Gross Profit, Adj.$418.5M$58.2M$53.0M$49.8M$150.1M
YoY %+252.1%-86.1%-8.9%-6.2%+201.7%
Margin %89.0%51.6%58.8%59.7%88.1%
EV / Gross Profit3.4x20.3x19.4x10.7x7.0x
EBITDA, Adj.$167.0M$-250.0M$-250.8M$-215.0M$-145.6M
YoY %+261.9%-249.7%-0.3%+14.3%+32.3%
Margin %35.5%-221.8%-277.9%-258.1%-85.4%
EV / EBITDA8.6x-4.7x-4.1x-2.5x-7.3x
EBIT$160.0M$-262.9M$-268.1M$-233.3M$-161.2M
YoY %+234.2%-264.3%-2.0%+13.0%+30.9%
Margin %34.0%-233.2%-297.1%-280.0%-94.6%
EV / EBIT9.0x-4.5x-3.8x-2.3x-6.6x
Net Income$127.8M$-280.3M$-263.5M$-227.1M$-193.9M
YoY %+214.9%-319.3%+6.0%+13.8%+14.6%
Net Margin27.2%-248.7%-292.0%-272.5%-113.8%
EPS (GAAP)$2.91-$6.50-$6.02-$4.59-$3.76
YoY %+197.7%-323.4%+7.4%+23.8%+18.1%